

Content available at: <https://www.ipinnovative.com/open-access-journals>

Indian Journal of Clinical and Experimental Ophthalmology

Journal homepage: www.ijceo.org

Original Research Article

The relationship of central macular thickness with clinical grades of diabetic retinopathy

Shivani Gupta¹, Mukesh Singh Rajpoot¹, Shweta Aloney², Pritee Chouhan¹,
Manoj Tyagi^{1,*}¹Dept. of Ophthalmology, Government Medical College, Datia, Madhya Pradesh, India²Datta Meghe Institute of Higher Education & Research, Wardha, Maharashtra, India

ARTICLE INFO

Article history:

Received 08-05-2023

Accepted 24-06-2023

Available online 29-09-2023

Keywords:

Central macular thickness

Diabetic retinopathy

Diabetic macular edema

ABSTRACT

Aim: To assess central macular thickness (CMT) in diabetics with or without diabetic retinopathy (DR) and compare it with various clinical grades of DR.**Materials and Methods:** All patients attending the ophthalmic OPD fulfilling the inclusion and met no exclusion criteria were enrolled in this study. All eyes underwent comprehensive and standardized ophthalmic examination. The CMT was measured using spectral domain optical coherence tomography using Cirrus HD OCT Model 500.**Result:** The mean CMT in cases is significantly greater than controls. It is also significantly greater in diabetics with DR as compared to diabetics without DR and it significantly varies with various grades of DR. The mean CMT is also increased in patients with diabetic macular edema (DME) and panretinal photocoagulation (PRP) untreated DR as compared to diabetics without DME and PRP treated DR respectively.**Conclusion:** Central macular thickness can be used as an indicator to monitor individuals with diabetes as it increased in diabetics and the presence of macular edema decreased in PRP treated eyes. It also varies with various grades of DR.This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.For reprints contact: reprint@ipinnovative.com

1. Introduction

Diabetic retinopathy is a common sight threatening retinopathy that occurs due to abnormalities of the retinal blood vessels and capillaries in a person with diabetes. It is a leading cause of vision loss across the world.^{1,2} The development of proliferative retinopathy and macular edema among diabetics are the most important causes of impaired vision.

The macula at the center is the most sensitive part of the retina responsible for the changes in vision. In patients with diabetes, breakdown of the inner blood retinal barrier

results in outpourings, leakage and accumulation of lipid exudates within the layers of the retina which end up causing macular edema. This certainly is considered the most important contributing factor to reduced visual acuity in diabetic retinopathy (DR). Therefore, it is crucial to assess central macular thickness.³

Until recently, slit-lamp bio-microscopy and stereoscopic photography were the available methods to evaluate macular thickness, but these methods did not provide a quantitative assessment of macular thickness. Recently, newer methods like optical coherence tomography (OCT) have emerged for measuring retinal thickness.⁴⁻⁹ OCT is a diagnostic technique that provides high-resolution cross-sectional imaging of the retina that comes up with consistent and

* Corresponding author.

E-mail address: guptashivani1994@gmail.com (M. Tyagi).

quantitative data on retinal thickness. It is being employed for the quantitative determination of macular edema in various diseases.¹⁰ In the given study we employed OCT to measure the central macular thickness (CMT), with the following aims: 1) to compare CMT in diabetics and age matched healthy controls; 2) to compare CMT in diabetics with and without retinopathy; 3) to assess the relationship in diabetic patients between CMT and stage of DR and diabetic macular edema (DME); 4) to compare CMT in treatment naïve DR and PRP treated DR patients who had history of last PRP session of more than 3 months after three months of PRP.

2. Materials and Methods

All patients with diabetes coming to ophthalmic OPD at a tertiary care center in central India from February 2019 to August 2020 who fulfilled the described inclusion criteria as well as met no exclusion criteria were involved in this study.

2.1. Inclusion criteria

1. Age more than or equal to 18 years.
2. Known diabetic with or without diabetic retinopathy (FBS \geq 120, PPBS \geq 180).
3. Age matched healthy controls.

2.2. Exclusion criteria

1. History of vitreoretinal surgery
2. Vitreoretinal disorders other than diabetic retinopathy currently or in the past.
3. Cataract surgery in the past 6 months.
4. Spherical equivalent of refractive error more than or equal to ± 6 D.
5. Any media opacity likely to cause attenuation of signal strength in OCT.
6. Signal strength $< 6/10$ in OCT.
7. PRP treated within 3 months
8. History of intravitreal anti-VEGF.

After taking a written informed consent, a comprehensive history was taken which included detailed ocular and systemic (duration of diabetes and antidiabetic medication) history, demography (age, sex) laterality, systemic comorbidities (hypertension, kidney disease). General examination and systemic examination of associated systemic diseases was done.

All patients underwent recording of BCVA, IOP evaluation by noncontact tonometer, and evaluation of both anterior and posterior segments using slit-lamp biomicroscope with a +90D lens which is being done after dilating the pupil with Tropic-P eye drops. Digital fundus photography, fundus fluorescein angiography, and OCT using cirrus HD OCT Model 500 were done and relevant

investigations were advised.

Patients were categorized as per the classification given by ETDRS, categorizing diabetic Retinopathy into mild, moderate and severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). Each patient with diabetic retinopathy was also grouped on the basis of whether they have diabetic macular edema (DME) or not. Patients were also divided into PRP untreated DR and PRP treated DR with history of last session of PRP of more than 3 months.

The CMT was measured using the SD-OCT technique. For quantitative estimation, the macula is divided into 9 ETDRS type regions each having a diameter of $500\mu\text{m}$ with an inner and outer ring, each of which is further partitioned into four quadrants, having outer radii of 1DD and 2DD respectively. The software in OCT identifies the inner and outer boundaries of the retina automatically and generates a pseudo color-scaled topographic map defining regions of increased thickness and decreased thickness in brighter and darker colors respectively. Both horizontal and vertical scans passing through the center of macula were analyzed. (Figure 1)




Fig. 1: OCT image of mild NPDR

2.3. Statistical analysis

The confined data was laid in MS Excel on a computer and the analysis was done using SPSS (Statistical Package for the Social Sciences version 20) for statistics. Student t-test and one-way ANOVA were applied to analyze quantitative variables.

3. Result

During the course of the study, a total of 400 eyes of 200 patients were included in the study which was categorized as 320 eyes of patients having diabetes and 80 eyes of age matched healthy controls.

Three twenty eyes were divided on the basis of severity of diabetic retinopathy into diabetics with no diabetic retinopathy (50 eyes), mild NPDR (60 eyes), moderate NPDR (62 eyes), severe NPDR (70 eyes), PDR (48 eyes) and PRP treated DR (30 eyes).

On the basis of the presence of macular edema patients were categorized as 75 eyes with DME and 195 eyes without DME.





Fig. 2: Shows the distribution of patients



The base line features of cases and controls including mean age, sex, duration of diabetes and mean BCVA were measured.

The mean CMT in patients with a history of diabetes was $291.28 \pm 105.98\mu\text{m}$ and in age matched healthy controls was $231.29 \pm 6.40 \mu\text{m}$. While comparing both the groups it was significantly greater in patients with diabetes as compared to healthy controls with $p \text{ value} < 0.001$. (Table 1)

Table 1: Shows central macular thickness according to the presence of diabetes mellitus

Group (n=400)	CMT (Mean \pm SD)	p value
Non-diabetic (n=80)	231.29 ± 6.40	<0.001
Diabetic (n=320)	291.28 ± 105.98	

When CMT was compared in diabetics with and without DR, it was found to be significantly greater in eyes with DR (mean CMT= $301.6 \pm 112.37\mu\text{m}$) as compared to eyes with no DR (mean CMT= $235.56 \pm 7.15\mu\text{m}$) with $p \text{ value} < 0.001$. (Table 2)

Table 2: Shows central macular thickness according to the presence of diabetic retinopathy

Group (n=320)	CMT (Mean \pm SD)	p value
DR Absent(n=50)	235.56 ± 7.15	<0.001
DR Present(n=270)	301.60 ± 112.37	

As mentioned above diabetic retinopathy was divided into various grades according to severity of DR. CMT was measured in various grades and the mean CMT values in no DR, mild NPDR, moderate NPDR, severe NPDR and PDR were $235.56 \pm 7.15 \mu\text{m}$, $297.83 \pm 125.47 \mu\text{m}$, $288.79 \pm 119.98 \mu\text{m}$, $339.26 \pm 117.98 \mu\text{m}$ and $307.88 \pm 90.88 \mu\text{m}$ respectively with all were having a $p \text{ value} < 0.001$ and it was decreased in the order as severe NPDR, PDR, mild NPDR, moderate NPDR and no DR. (Table 3)

Table 3: Shows central macular thickness according to the severity of diabetic retinopathy

Group (n=400)	CMT (Mean \pm SD)	p value
Non-diabetics (n=80)	231.29 ± 6.40	<0.001
Diabetics with no DR(n=50)	235.56 ± 7.15	
Mild NPDR (n=60)	297.83 ± 125.47	
Moderate NPDR (n=62)	288.79 ± 119.98	
Severe NPDR (n=70)	339.26 ± 117.98	
PDR(n=48)	307.88 ± 90.88	
PRP treated DR (n=30)	237.70 ± 14.86	

While assessing CMT in diabetic patients with and without DME, it increased significantly in eyes with DME (mean CMT= $448.96 \pm 121.98\mu\text{m}$) as compared to eyes without DME (mean CMT= $243.01 \pm 13.82 \mu\text{m}$) with $p \text{ value} < 0.001$. (Table 4)

Table 4: Shows central macular thickness according to the presence of diabetic macular edema

Group(n=320)	CMT (Mean \pm SD)	p value
DME Absent(n=195)	243.01 ± 13.82	<0.001
DME Present(n=75)	448.96 ± 121.98	

CMT was also assessed in PRP untreated DR and PRP treated DR, the mean CMT values in PRP untreated DR and PRP treated DR were $309.59 \pm 116.66\mu\text{m}$ and $237.70 \pm 14.86 \mu\text{m}$ respectively. It was significantly decreased in PRP treated DR as compared with PRP untreated DR with $p \text{ value} < 0.001$. (Table 5)

4. Discussion

Diabetic retinopathy is potentially a complication of diabetes mellitus causing blindness. The causes of visual loss are diabetic maculopathy and the complications of

Table 5: Shows central macular thickness in diabetic retinopathy patients with or without intervention (PRP)

Group (n=320)	CMT (Mean \pm SD)	p value <0.001
PRP untreated DR (n=240)	309.59 \pm 116.66	
PRP treated DR(n=30)	237.70 \pm 14.86	

PDR like vitreous hemorrhage, neovascular glaucoma and tractional retinal detachment.¹¹

The macula, at the center is the most sensitive part of the retina responsible for changes in vision. In patients with diabetes, the breakdown of inner blood retinal barrier results in outpourings, seepage and accumulation of lipid exudates within the layers of the retina resulting in macular edema. This is certainly considered as the major contributing factor of diminution of vision in diabetic retinopathy. Therefore, it is crucial to assess central macular thickness.³

OCT has evolved as a crucial technique that aids in the assessment as well as the management of retinal disease. Its noninvasive character and ability to do in vivo imaging of intraocular structures with a resolution closer to that of histological sections, has made it very useful particularly in detecting and quantifying macular pathologies.

While comparing the CMT in diabetics with age matched healthy controls it was found to be significantly greater in diabetics (mean CMT=291.28 \pm 105.98 μ m) as compared to healthy controls (mean CMT=231.29 \pm 6.40 μ m) with p value<0.001. Abrar F et al³ found the results comparable to our study. Demir M et al¹² found no significant difference between the two groups.

In diabetics, the increase in macular thickness in comparison to the healthy control, could be depicted by seeing the pathophysiology of DR. The changes in the glucose metabolism are responsible for the alterations in the capillary walls of retinal blood vessels that sequentially destroy blood retinal barrier that further leads to hemorrhages and leakage of exudates that can be seen by OCT as a detectable thickening of the retina.

While comparing CMT in diabetics with and without DR, it showed significantly greater values in eyes with DR as compared to eyes with no DR.

As mentioned above diabetic retinopathy was divided into various grades according to severity of DR. The mean CMT values significantly decreased in the order as severe NPDR, PDR, mild NPDR, moderate NPDR and no DR. Abrar F et al³ found that CMT increases with increasing severity of DR.

The exact reason for the differences in findings of our study and previously done study is not known. The maximum CMT in severe NPDR might be due to presence of maximum number of patients having DME in this group in our study because when mean CMT in eyes with severe NPDR without DME compared with PDR without DME,

it was found to be significantly greater in eyes with PDR without DME (mean CMT=264 \pm 7.07 μ m) than in eyes with severe NPDR without DME (mean CMT=255.89 \pm 6.97 μ m).

When CMT was compared in diabetic patients with and without DME, it was increased significantly in eyes with DME as compared to eyes without DME. Sudhalkar A et al¹³ noticed similar findings as found in our study.

While assessing CMT in PRP untreated and PRP treated DR, it was significantly decreased in PRP treated DR as compared with PRP untreated DR. Mukhtar A et al¹⁴ observation was consistent with our study. Lee SB et al¹⁵ showed observation against our study.

5. Limitations

1. Owing to the smaller sample size generalizability of the results is not feasible for the diabetic population.
2. Type 1 or type 2 diabetes were not distinguished, which vary in pathophysiology and treatment that might lead to variation in macular thickness measurements.
3. The duration of diabetes, the type and dosage of systemic treatment and the presence of diabetic nephropathy has not been considered in this study.

6. Conclusion

In conclusion, the central macular thickness can be used as an indicator to monitor diabetic individuals as it is increased in diabetics, and the presence of macular edema is decreased in PRP treated eyes. It also varied with different grades of DR.

7. Source of Funding

None.

8. Conflict of Interest

None.

References

1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. *Ophthalmology*. 1998;105(6):998–1003.
2. Maurya RP. Diabetic retinopathy: My Brief Synopsis. *Indian J Clin Exp Ophthalmol*. 2015;1(4):189–90.
3. Abrar F, Rastogi PS, Ansari M. Central Macular Thickness in Diabetic Retinopathy-A Comparative Study. *Ann Int Med Dent Res*. 2017;3(2):1.
4. Zeimer RC, Mori MT, Khoobehi B. Feasibility test of a new method to measure retinal thickness noninvasively. *Invest Ophthalmol Vis Sci*. 1989;30(10):2099–105.
5. Shahidi M, Ogura Y, Blair NP, Rusin MM, Zeimer R. Retinal thickness analysis for quantitative assessment of diabetic macular edema. *Arch Ophthalmol*. 1991;109(8):1115–9.
6. Zeimer R, Shahidi M, Mori M, Zou S, Asrani S. A new method for rapid mapping of the retinal thickness at the posterior pole. *Invest Ophthalmol Vis Sci*. 1996;37(10):1994–2001.

7. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. *Science*. 1991;254(5035):1178–81.
8. Hee MR, Izatt JA, Swanson EA, Huang D, Schuman JS, Lin CP, et al. Optical coherence tomography of the human retina. *Arch Ophthalmol*. 1995;113(3):325–32.
9. Murthy RK, Haji S, Sambhav K, Grover S, Chalam KV. Clinical applications of spectral domain optical coherence tomography in retinal diseases. *Biomed J*. 2016;39(2):107–20.
10. Lattanzio R, Brancato R, Pierro L, Bandello F, Iaccheri B, Fiore T, et al. Macular thickness measured by optical coherence tomography (OCT) in diabetic patients. *Eur J Ophthalmol*. 2002;12(6):482–7.
11. Nentwich MM, Ulbig MW. Diabetic retinopathy-ocular complications of diabetes mellitus. *World J Diabetes*. 2015;6(3):489–99.
12. Demir M, Oba E, Dirim B, Ozdal E, Can E. RETRACTED ARTICLE: Central macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy. *BMC Ophthalmol*. 2013;13(1):1–4.
13. Sudhalkar A, Chhablani JK, Venkata A, Raman R, Rao PS, Jonnadula GB. Choroidal thickness in diabetic patients of Indian ethnicity. *Indian J Ophthalmol*. 2015;63(12):912–6.
14. Mukhtar A, Khan MS, Junejo M, Ishaq M, Akbar B. Effect of pan retinal photocoagulation on central macular thickness and visual acuity in proliferative diabetic retinopathy. *Pak J Med Sci*. 2016;32(1):221–4.
15. Lee SB, Yun YJ, Kim SH, Kim JY. Changes in macular thickness after panretinal photocoagulation in patients with severe diabetic retinopathy and no macular edema. *Retina*. 2010;30(5):756–60.

Author biography

Shivani Gupta, Senior Resident

Mukesh Singh Rajpoot, Assistant Professor

Shweta Aloney, Senior Resident

Pritee Chouhan, Senior Resident

Manoj Tyagi, Associate Professor

Cite this article: Gupta S, Rajpoot MS, Aloney S, Chouhan P, Tyagi M. The relationship of central macular thickness with clinical grades of diabetic retinopathy. *Indian J Clin Exp Ophthalmol* 2023;9(3):334–338.